Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid
tumours and poses an unsolved problem in cancer medicine. Despite the recent success of …

Pancreatic ductal adenocarcinoma is a stroma-rich and highly challenging cancer to treat.
Over recent years, it has become increasingly evident that the complex network of soluble …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …

Pancreatic ductal adenocarcinoma (PDAC) belongs to the most lethal solid tumors in
humans. A histological hallmark feature of PDAC is the pronounced tumor microenvironment …

Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …

Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumours
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies and is
characterized by a unique tumor microenvironment (TME) consisting of an abundant stromal …

Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United
States and in the world. Late diagnosis, early metastasis and lack of effective therapy are …

Pancreatic ductal adenocarcinoma (PDA) is an almost uniformly lethal disease. One
explanation for the devastating prognosis is the failure of many chemotherapies, including …